Showing results (981-990 of 2,158) with videos related to
Sort By:
Pageof 216
Journal of Biopharmaceutical Statistics|February 18, 2026
Win statistics (win ratio, win odds, and net benefit): Noncollapsibility and standardization for randomized clinical trialsGaohong Dong, Margaret Gamalo-Siebers, Ying Cui, et al.Journal of Biopharmaceutical Statistics|February 10, 2026
Application of principal stratification in crossover and parallel clinical trial designsBahareh Afhami, Mohsen Madadi, Mohsen Rezapour, et al.Journal of Biopharmaceutical Statistics|February 28, 2025
Optimal dose selection in phase I/II dose finding trial with contextual bandits: a case study and practical recommendationsJixian Wang, Ram TiwariJournal of Biopharmaceutical Statistics|January 27, 2025
Bayesian method for comparing F1 scores in the absence of a gold standardJun Tamura, Yusuke Saigusa, Junichi Fujita, et al.Journal of Biopharmaceutical Statistics|November 17, 2024
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncologyHao Sun, Hsin-Yu Lin, Jieqi Tu, et al.Journal of Biopharmaceutical Statistics|November 29, 2024
DOD-BART: machine learning-based dose optimization design incorporating patient-level prognostic factors via Bayesian additive regression treesYunqi Zhao, Rachael Liu, Jianchang Lin, et al.Journal of Biopharmaceutical Statistics|March 13, 2025
Efficient estimation of the cox model when incorporating the subgroup restricted mean survival timeJo-Ying Hung, Junjiang Zhong, Huang-Tz Ou, et al.Journal of Biopharmaceutical Statistics|October 8, 2024
On approximate equality of Z-values of the statistical tests for win statistics (win ratio, win odds, and net benefit)Gaohong Dong, Ying Cui, Margaret Gamalo-Siebers, et al.Journal of Biopharmaceutical Statistics|June 18, 2024
Drug safety assessment by machine learning modelsNan Miles Xi, Dalong Patrick HuangJournal of Biopharmaceutical Statistics|June 22, 2024
The generalized order statistics arising from three populations with the lower truncated proportional hazard rate models and its application to the sensitivity to the early disease stageHossein Nadeb, Hamzeh Torabi, Yichuan Zhao, et al.Pageof 216